Ruthenium-106 brachytherapy and central uveal melanoma
International Ophthalmology · 2025
DOI: 10.1007/s10792-024-03381-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Ophthalmology, 2025. Verfasst von Luise Grajewski und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane, Dessau, Germany. Luise.grajewski@klinikum-dess…. Hauptthemen laut MEDLINE: Brachytherapy, Melanoma, Uveal Neoplasms, Ruthenium Radioisotopes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medizinische Hochschule Brandenburg CAMPUS GmbH.
Abstract (Originalsprache)
Purpose
Uveal melanoma (UM) is the most common primary ocular malignancy. The size and location of the tumor are decisive for brachytherapy with the β-emitting ruthenium-106 (Ru-106) plaque. The treatment of juxtapapillary and juxtafoveolar UM may be challenging because of the proximity or involvement of the macula and optic nerve and high recurrence rates.
Methods
Central UMs were defined as lesions up to 5 mm off the optic disc or fovea radius of 5 mm. Between January 2011 and July 2020, we treated 56 patients with Ru-106-brachytherapy. The clinical outcomes for recurrence, visual acuity, and radiation-related toxicity were assessed. The follow-up was 66 (6–136) months.
Results
Of the 56 patients (56 eyes), 8 (14%) suffered from local recurrence. Six relapsing UM in 19 (32%) patients were located close to the optic disc, and two patients had UM close to the macula (2/37, 5%) ( p > 0.05). The overall eye-preservation rate was 89%. The pretreatment visual acuity (VA) was 0.45 and reduced to 0.26 after brachytherapy. Radiation retinopathy or optic neuropathy was detected in 7 (13%) patients and radiation maculopathy in 10 (17.9%). Six patients (11%) underwent enucleation for recurrence or radiation-induced ophthalmopathy.
Conclusion
Central UMs are challenging to treat. UMs should be categorized as lesions laterally or medially to the fovea because of different long-term control rates. Localization near the optic disc requires thoughtful management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane, Dessau, Germany. Luise.grajewski@klinikum-dessau.de.
- Department of Ophthalmology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane, Dessau, Germany.
- Department of Radiation Oncology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane, Dessau, Germany.
Förderung
- Medizinische Hochschule Brandenburg CAMPUS GmbH
Zitieren
APA
Grajewski, L., Kneifel, C., Wösle, M., Ciernik, I. F., & Krause, L. (2025). Ruthenium-106 brachytherapy and central uveal melanoma. International Ophthalmology. https://doi.org/10.1007/s10792-024-03381-6
Vancouver
Grajewski L, Kneifel C, Wösle M, Ciernik IF, Krause L. Ruthenium-106 brachytherapy and central uveal melanoma. International Ophthalmology. 2025. doi:10.1007/s10792-024-03381-6
BibTeX
@article{Grajewski2025,
author = {Grajewski, Luise and Kneifel, Christiane and Wösle, Markus and Ciernik, Ilja F and Krause, Lothar},
title = {Ruthenium-106 brachytherapy and central uveal melanoma},
journal = {International Ophthalmology},
year = {2025},
doi = {10.1007/s10792-024-03381-6}
}
EUVIMED